Clinical Trials Browser

Phase 1 × Inflammation × Clear all

Breast Neoplasms, Inflammation, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT06065592 2023-10-06

CAT_PB

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Cardiovascular Diseases, Colonic Neoplasms, Carcinoma, Hepatocellular, Immune System Diseases, Inflammation, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Thromboembolism, Thrombosis

NCT04626843 2023-02-14

Intermittent Fasting and CLL/SLL

Phase 1 Completed

15 enrolled

LymphoidOther hematologic neoplasm

Intermittent Fasting, Feeding Behavior, Inflammation, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02134600 2018-08-28

OmegaChild

Phase 1 Completed

40 enrolled

Inflammation, Neoplasms

NCT01489319 2017-02-10

ELI-ROAS

Phase 1 Terminated

47 enrolled

Inflammation, Insulin Resistance, Polycystic Ovary Syndrome, Hyperandrogenism

NCT02229201 2014-09-01

Comparison of Two Anaesthetics on Brain During Brain Tumour Surgery

Phase 1 Completed

40 enrolled

Inflammation

NCT01089998 2013-01-21

PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations

Phase 1 Completed

35 enrolled

Inflammation, Neoplasms

NCT01297088 2013-01-21

PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.

Phase 1 Completed

24 enrolled

Inflammation, Neoplasms

NCT00817752 2010-03-18

Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation

Phase 1 Completed

25 enrolled

Autoimmune Diseases, Inflammation, Neoplasms

Clinical Trials

PTST_PALBEVA

CAT_PB

Intermittent Fasting and CLL/SLL

OmegaChild

ELI-ROAS

Comparison of Two Anaesthetics on Brain During Brain Tumour Surgery

PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations

PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.

Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation